Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions

Oncologist

Volumn 13, Issue SUPPL. 3, 2008, Pages 27-32

  Spano, Jean Philippe ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anemia; Erythropoiesis Stimulating agents; Transfusions

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; CHEMICALLY INDUCED DISORDER; NEOPLASM;

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMOGLOBINS; HUMANS; NEOPLASMS;

EID: 54049148231     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S3-27     Document Type: Review

References (34)

1. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(suppl 2):13-19.
2. Pecorelli S. Suboptimal hemoglobin levels: Do they impact patients and their therapy? Introduction. Semin Oncol 2000;27(suppl 4): 1-3.
3. Visovsky C, Schneider SM. Cancer-related fatigue. Online J Issues Nurs 2003:8:8.
4. Caro JJ. Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-2221.
5. Alexanian R, Balcerzak S, Bonnet JD et al. Prognostic factors in multiple myeloma. Cancer 1975;36:1192-1201.
6. Ludwig H, Fritz E. Anemia of cancer patients: Patient selection and patient stratification for epoetin treatment. Semin Oncol 1998;25(suppl 7):35-38.
7. Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25(suppl 7):2-6.
8. Ludwig H, Van Belle S. Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer2004;40:2293-2306.
9. Crawford J. Rescue by Transfusion Versus an Improvement/Maintenance Strategy With ESAs: A Conceptual Model. Clinical Perspectives on ESAs (May 10.2007 slides). Available at http://www.fda.gov/ohrms/dockets/ ac/07/slides/2007-4301s2-00-index.htm. Accessed April 18, 2008.
10. Vaupel P. Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. The Oncologist 2008;13(suppl 3):21-26.
11. Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001;8:405-410.
12. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998;25(suppl 7):43-46.
13. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemia patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
14. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
15. Agency for Healthcare Research and Quality. Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment. May 2006. Available at http://www.ahrq.gov/ news/press/pr2006/epopr. htm. Accessed April 18, 2008.
16. Boogaerts M. Coiffier B, Kainz C; Epoetin beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-995.
17. Case DC Jr, Bukowski RM, Carey RW et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-806.
18. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995;86:4446-4453.
19. Cazzola M, De Stefano P, Ponchio L et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haematol 1995;89:473-478.
20. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179.
21. Henry DH, Brooks BJ Jr, Case DC Jr et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-260.
22. Littlewood TJ. Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
23. Oberhoff C, Neri B, Amadori D et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 1998;9:255-260.
24. Osterborg A. Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996;87:2675-2682.
25. Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
26. Rose E, Rai K, Revicki D et al. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetinalfa(EPO). Blood 1994;84(suppl 10):526a.
27. Bamias A, Aravantinos G, Kalofonos C et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-110.
28. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23:2597-2605.
29. Iconomou G, Koutras A, Rigopoulos A et al. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial. J Pain Symptom Manage 2003;25:512-518.
30. Savonije JH, van Groeningen CJ. Wormhoudt LW et al. Early intervention with epoetin alfa during platinum-based chemotherapy: An analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data. The Oncologist 2006;11:197-205.
31. Quirt I, Kovacs M, Couture F et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience. The Oncologist 2006;11:73-82
32. Couture F. Turner AR, Melosky B et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. The Oncologist 2005;10:63-71.
33. Waltzman R, Croot C. Justice GR et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. The Oncologist 2005;10:642-650.
34. Gascon PJ. Jones M, Justy J. Once-weekly 40,0001U epoetin alfa mixed tumor studies: Meta-analysis. Ann Oncol 2006;17:294.